share_log

ARS Pharmaceuticals Q4 2023 GAAP EPS $(0.57) Misses $(0.14) Estimate

ARS Pharmaceuticals Q4 2023 GAAP EPS $(0.57) Misses $(0.14) Estimate

ARS Pharmaceuticals 2023年第四季度GAAP每股收益美元(0.57)未达到预期(0.14)美元
Moomoo 24/7 ·  03/21 16:17

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.14) by 307.14 percent.

ARS Pharmicals(纳斯达克股票代码:SPRY)公布的季度亏损为每股0.57美元,比分析师普遍预期的0.14美元(0.14美元)低307.14%。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发